Publication
Essential Corporate News - Week ending 18 October 2024
On 14 October 2024, the Department for Business and Trade (DBT) published the Report of an independent expert Panel on how best to establish a UK corporate re-domiciliation regime.
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Publication
On 14 October 2024, the Department for Business and Trade (DBT) published the Report of an independent expert Panel on how best to establish a UK corporate re-domiciliation regime.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023